Zantac ruling throws a "significant spanner into the works" for GSK
(Alliance News) - An adverse US court ruling regarding GSK PLC's heartburn drug, Zantac, was a "surprise," and will, in the short-term, pour "more uncertainty over the investment case," analysts on Monday said. Read More